IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 70.3

Change

-0.15 (-0.21)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.31 (-0.20%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

-0.08 (-0.11%)

USD 2.97B
FXH First Trust Health Care AlphaD..

-0.78 (-0.71%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.33 (-0.37%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.03 (+0.12%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.02 (+0.06%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-0.11 (-0.12%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.02 (-0.06%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.70 (+1.13%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.05 (+0.18%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.75% 95% A 67% D+
Dividend Return 1.50% 100% F 30% F
Total Return 15.26% 100% F 64% D
Trailing 12 Months  
Capital Gain 21.32% 62% D 55% F
Dividend Return 1.83% 100% F 26% F
Total Return 23.15% 67% D+ 50% F
Trailing 5 Years  
Capital Gain 49.74% 57% F 69% C-
Dividend Return 8.59% 94% A 28% F
Total Return 58.33% 62% D 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.38% N/A N/A 59% D-
Dividend Return 7.74% N/A N/A 56% F
Total Return 1.36% N/A N/A 32% F
Risk Return Profile  
Volatility (Standard Deviation) 11.19% N/A N/A 75% C
Risk Adjusted Return 69.20% N/A N/A 83% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike